In the pharmaceutical industry, change is an ever-present force. That’s why at Neuland, we recognize the need to not only keep pace with this evolution but to proactively lead it….
So far, 2024 has been a roller coaster for the pharma industry. We’ve seen layoffs, recalls, outbreaks, criticism of weight-loss drugs—and we still have three-quarters of the year to go….
Technology transfer from pharmaceutical companies to contract development and manufacturing organizations (CDMOs), is critical to successful drug development. When you consider the skills, knowledge, intellectual property, technologies, and manufacturing methodologies being…
A company’s ability to pivot and adapt — its agility — is more than just an asset. In today’s dynamic contract manufacturing landscape, it’s a necessity. Agility allows a CDMO…
Welcome to Part 2 of our series on managing API particle size. (You can find Part 1 here.) Today we’re talking about some of the new and emerging technologies that…
API particle size is a key consideration in manufacturing quality pharmaceutical products, however, particle size is also notoriously difficult to control during manufacturing. Despite the difficulty, it’s essential to get…
Selecting the right pharmaceutical contract manufacturing partner for Phase 3 clinical and commercial supply is challenging. There are several critical qualifiers you need to consider: Do they have the expertise…
Specialty drug APIs are both a blessing and a challenge for pharmaceutical companies. They are essential for treating patients and saving lives. The demand for them is high, which promises…
To be successful, pharmaceutical innovators and biotech organizations need to optimize production and achieve higher yields of their active pharmaceutical ingredients to make products more cost-effective. To realize these results,…
The development of drug substances heavily depends on a thorough and precise understanding of its different processes. One of these critical steps is crystallization, which has a significant impact on…
